Sleep disturbances in the rotenone animal model of Parkinson disease

Brain Research

Volumn 1042, Issue 2, 2005, Pages 160-168

  García García, Fabio ^a   Ponce, Sonia ^a   Brown, Richard ^a   Cussen, Victoria ^a   Krueger, James M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Dimethyl sulfoxide; Dopaminergic cells; L dopa; Polyethylene glycol; Rotenone; Sleep

Indexed keywords

LEVODOPA; ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; NERVE CELL DEGENERATION; NONHUMAN; NONREM SLEEP; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REM SLEEP; SLEEP; SLEEP DISORDER;

EID: 17844386063     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.02.036     Document Type: Article

References (40)

1. M. Alam, and W.J. Schmidt Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats Behav. Brain Res. 136 2002 317 324
2. J.J. Askenasy Reversals of sleep disturbances in Parkinson's disease by antiparkinsonian therapy: a preliminary study Neurology 35 1985 527 532
3. J.J. Askenasy Sleep in Parkinson's disease Acta Neurol. Scand. 87 1993 167 170
4. J.J. Askenasy Sleep disturbances in Parkinsonism J. Neural Transm. 110 2003 125 150
5. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 12 2000 1301 1306
6. T.N. Chase, T.M. Engber, and M.M. Mouradian Striatal dopaminoceptive system changes and motor response complications in l-dopa-treated patients with advanced Parkinson's disease Adv. Neurol. 60 1993 181 185
7. S.Y. Choi, H.D. Chae, T.J. Park, H. Ha, and K.T. Kim Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation Br. J. Pharmacol. 126 1999 1050 1056
8. A.A. Corona-Morales, A. Castell, and L. Zhang L-DOPA-induced neurotoxic and apoptotic changes on cultured chromaffin cells NeuroReport 11 2000 503 506
9. L.E. DeForge, J.C. Fantone, J.S. Kenney, and D.G. Remick Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood J. Clin. Invest. 90 1992 2123 2129
10. R.J. Ferrante, J.B. Schulz, N.W. Kowall, and M. Flint Beal Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra Brain Res. 753 1997 157 162
11. H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease J. Neurochem. 81 2002 1285 1297
12. H.M. Gao, J.S. Hong, W. Zhang, and B. Liu Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons J. Neurosci. 22 2002 782 790
13. F. García-García, H. Yoshida, and J.M. Krueger Interleukin-8 promotes non-rapid eye movement sleep in rabbits and rats J. Sleep Res. 13 2004 55 61
14. E.C. Hirsch, G. Hoglinger, E. Rousselet, T. Breidert, K. Parain, J. Feger, M. Ruberg, A. Prigent, C. Cohen-Salmon, and J.M. Launay Animal models of Parkinson's disease in rodents induced by toxins: an update J. Neural Transm., Suppl. 65 2003 89 100
15. G.U. Hoglinger, J. Feger, A. Prigent, P.P. Michel, K. Parain, P. Champy, M. Ruberg, W.H. Oertel, and E.C. Hirsch Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats J. Neurochem. 84 2003 491 502
16. A. Kales, R.D. Ansel, C.H. Markham, M.B. Scharf, and T.L. Tan Sleep in patients with Parkinson's disease and normal subjects prior to and following levedopa administration Clin. Pharm. Ther. 12 1971 397 406
17. Y. Kitamura, J. Kakimura, and T. Taniguchi Antiparkinsonian drugs and their neuroprotective effects Biol. Pharm. Bull. 25 2002 284 290
18. N. Kleitman Sleep and Wakefulness Midway Reprint 1963 The University of Chicago Press Chicago
19. T. Kodama, and Y. Honda Acetylcholine and glutamate release during sleep-wakefulness in the pedunculopontine tegmental nucleus and norepinephrine changes regulated by nitric oxide Psychiatry Clin. Neurosci. 53 1999 109 111
20. J.M. Krueger, F.J. Obal, J. Fang, T. Kubota, and P. Taishi The role of cytokines in physiological sleep regulation Ann. N. Y. Acad. Sci. 933 2001 211 221
21. N. Lapointe, M. St-Hilaire, M.G. Martinoli, J. Blanchet, P. Gould, C. Rouillard, and F. Cicchetti Rotenone induces non-specific central nervous system and systemic toxicity FASEB J. 18 2004 717 719
22. A.D. Lowe Sleep in Parkinson's disease J. Psychosom. Res. 44 1998 613 617
23. M.C. Michel Concomitant regulation of Ca++ mobilization and Gi3 expression in human erythroleukemia cells Eur. J. Pharmacol. 348 1998 135 141
24. A. Mura, M. Mintz, and J. Feldon Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (l-DOPA) administration in rats with unilateral lesions of the nigrostriatal system Exp. Neurol. 177 2002 252 264
25. H. Onoe, Y. Watanabe, K. Ono, Y. Koyama, and O. Hayaishi Prostaglandin E2 exerts an awaking effect in the posterior hypothalamus at a site distinct from that mediating its febrile action in the anterior hypothalamus J. Neurosci. 12 1992 2715 2725
26. P.K. Pal, S. Calne, A. Samii, and J.A.E. Fleming A review of normal sleep and its disturbances in Parkinson's disease Parkinsonism Relat. Disord. 5 1999 1 17
27. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates second ed. 1982 Academic Press Sydney
28. C. Perier, J. Bove, M. Vila, and S. Przedborski The rotenone model of Parkinson's disease Trends Neurosci. 26 2003 345 346
29. R. Pfeiffer Optimization of levedopa therapy Neurology 42 1992 39 43
30. A. Priyadarshi, S.A. Khuder, E.A. Schaub, and S. Shrivastava A meta-analysis of Parkinson's disease and exposure to pesticides Neurotoxicology 21 2000 435 440
31. A. Priyadarshi, S.A. Khuder, E.A. Schaub, and S.S. Priyadarshi Environmental risk factors and Parkinson's disease: a metaanalysis Environ. Res. 86 2001 122 127
32. S.A. Saeed, S.J. Karimi, and A. Suria Differential effects of dimethyl sulfoxide on human platelet aggregation and arachidonic acid metabolism Biochem. Med. Metab. Biol. 40 1988 143 150
33. N.C. Santos, J. Figueira-Coelho, J. Martins-Silva, and C. Saldanha Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects Biochem. Pharmacol. 65 2003 1035 1041
34. L.C. Schmued, C. Albertson, and W. Slikker Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration Brain Res. 751 1997 37 46
35. T.B. Sherer, R. Betarbet, J.H. Kim, and J.T. Greenamyre Selective microglial activation in the rat rotenone model of Parkinson's disease Neurosci. Lett. 341 2003 87 90
36. T.B. Sherer, J.H. Kim, R. Betarbet, and J.T. Greenamyre Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation Exp. Neurol. 179 2003 9 16
37. M.N. Shouse, and J.M. Siegel Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep Brain Res. 571 1992 50 63
38. Y. Smith, M.D. Bevan, E. Shink, and J.P. Bolam Microcircuitry of the direct and indirect pathways of the basal ganglia Neuroscience 86 1998 353 387
39. A. Tan, M. Salgado, and S. Fahn Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa Mov. Disord. 11 1996 214 216
40. M. Tanaka, A. Sotomatsu, H. Kanai, and S. Hirai Dopa and dopamine cause cultured neuronal death in the presence of iron J. Neurol. Sci. 101 1991 198 203